Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
Investors who lost money on Alnylam Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - ALNY
07:30am, Thursday, 28'th Mar 2024
NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v
Alnylam Being Investigated on Behalf of Alnylam Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
07:20am, Tuesday, 26'th Mar 2024
NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KA
Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal
12:30pm, Wednesday, 06'th Mar 2024
Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.
Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
01:11pm, Friday, 16'th Feb 2024
Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript
01:16pm, Thursday, 15'th Feb 2024
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript
Why Alnylam Pharmaceuticals Stock Is Sinking Today
12:39pm, Thursday, 15'th Feb 2024
Alnylam reported mixed fourth-quarter results. The company also announced changes to its Helios-B phase 3 study of vutrisiran in ATTR-CM.
Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say
11:31am, Thursday, 15'th Feb 2024
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compar
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Thursday, 08'th Feb 2024
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam's Huge Opportunity
10:35am, Friday, 12'th Jan 2024
Pfizer's drug tafamidis has shown positive results in treating transthyretin amyloidosis cardiomyopathy (ATTR-CM), but there is still room for improvement. Alnylam's gene silencer treatments, ONPATTRO
Alnylam (ALNY) Posts Preliminary Q4 & Full-Year '23 Revenues
03:02pm, Monday, 08'th Jan 2024
Alnylam (ALNY) reports preliminary full-year and fourth-quarter 2023 net product revenues.
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
07:30am, Tuesday, 02'nd Jan 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
3 biotech powerhouses poised to thrive amid sector rebound
10:11am, Friday, 08'th Dec 2023
The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant rally a
Alnylam to Webcast Virtual R&D Day
08:00am, Wednesday, 06'th Dec 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the I
